RSS

cystic fibrosis

A clinical trial has been started to evaluate and validate a urine-based point of care (POC) diagnostic from Mologic, aimed at helping cystic fibrosis (CF) patients monitor and manage their condition at home. Read more

Technology

Motif Bio has received an award from the Cystic Fibrosis Foundation, which will fund important in vitro testing to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis Read more

News

Motif Bio’s investigational drug candidate, iclaprim, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. Read more

News

Concert Pharmaceuticals has initiated a phase one multiple ascending dose clinical trial with CTP-656 for cystic fibrosis Read more

News

US group Savara Pharmaceuticals has secured $10 million in financial backing to develop AeroVanc, the trade name of the first inhaled antibiotic designed to address the growing number of MRSA lung infections in cystic fibrosis patients. Read more

The Phase III confirmatory trial is referred to as ACT CF (ataluren confirmatory trial in cystic fibrosis) and the primary endpoint is lung function as measured by relative change in percent predicted forced expiratory volume in one second, or FEV1. Read more

News